Field report SW-86 / L7 · sheet /expansion

Expansion & MarketsFiled from the territory

British Business Bank Puts £1.1bn Behind UK Life Sciences

The British Business Bank has committed £1.1bn to UK life sciences, including its biggest single bet of £25m, as it courts pension funds to back the sector.

Grid
SW-86 / L7
Surveyed
November 18, 2026
Reading
4 min read
Correspondent
Priya Raman
British Business Bank ‘throws kitchen sink’ at life sciences to address dearth of UK investment
Fig. SW-86 / L7British Business Bank ‘throws kitchen sink’ at life sciences to address dearth of UK investment — Belova59 / pixabay

Field notes

  1. The British Business Bank has committed £1.1bn to life sciences: £832m across 20 funds plus £302m into domestic scale-ups.
  2. Its £25m investment in Alchemab Therapeutics is its largest in a life science firm to date; T-Therapeutics received £15m.
  3. 70 per cent of the £11.1bn committed to UK private markets has gone to property; private equity got just £500m.
  4. The National Wealth Fund committed £147m of debt financing to One North Quay, a Canary Wharf science building due in 2028.

The British Business Bank has pushed its total commitment to UK life sciences to £1.1bn, a figure it says reflects a deliberate decision to "throw the kitchen sink at the problem" of financing a sector that British money has long underfunded.

The state-owned lender's backing splits into two pots. Some £832m is spread across 20 dedicated life science funds, while £302m has gone directly into domestic scale-ups — companies past the startup stage that need bigger cheques to grow. The point of both, chief investment officer Leandros Kalisperas told City AM, is to pull in more institutional money and help British firms scale at home rather than sell up or move abroad.

Where the money has landed

Recent deals show the bank's appetite. It put £25m into Alchemab Therapeutics, its single largest investment in a life science firm to date, and £15m into T-Therapeutics, a Cambridge University spinout (a company created to commercialise research from the university).

The bank also committed €58m (£48.3m) to Sofinnova Crossover Fund II, a Paris-based fund investing across Europe. That may look like a detour for a domestic-focused lender. Kalisperas argues it isn't.

"You can't back venture in the UK by just investing in managers that only invest in the UK," he said. "Within life sciences we have to acknowledge that there are European specialists in this space. We have to encourage them to invest in UK companies. Why wouldn't we as a limited partner want them to do that?"

A limited partner, in this context, is an investor in a fund rather than the fund manager itself.

Why the pension push matters

The bigger prize is pension capital. The bank has been courting institutional investors, particularly signatories of the Mansion House accord, which saw 11 of the UK's top pension managers commit to putting five per cent of their assets into private markets and unlisted equities by 2030.

The early allocation data explains the urgency. Of the £11.1bn committed to UK private markets so far, 70 per cent has gone to property. Private equity received just £500m. Life sciences, which carries technical risk that generalist investors struggle to price, is getting a fraction of even that.

"Backing life science innovation adds extra complexity," Kalisperas said. "We are aiming…to communicate the possibilities for pension funds themselves to get involved."

Can the UK stop losing its biotechs?

The sector has a chronic habit of losing companies to overseas buyers who offer better funding and deeper scaling conditions. The bank's own portfolio hasn't escaped. Merck & Co, the US pharmaceutical giant, bought ophthalmology biotech Eyebio in 2024 in a deal worth up to $3bn (£2.2bn). Last year, Japan's Terumo acquired Orgonox, an Oxford University spinout, for $1.5bn.

Chris Molloy, chief executive of the Bio Industry Association, said the bank's expanded funding would "enable our most promising businesses to scale and stay in the UK".

What about the AI angle?

Kalisperas expects capital flows into life sciences to pick up as the AI investment cycle matures and the technology spreads into industries well beyond the AI sector itself. He sees a direct link between the two stories.

"People are going to be taking another look at life sciences because it is also linked in with AI… drug discovery can change through AI," he said. "I think there are a number of angles through which life sciences are hopefully going to get their moment."

Bricks as well as cheques

The funding news follows a related move earlier this week. The National Wealth Fund committed £147m of debt financing to One North Quay in Canary Wharf, set to become one of the largest commercial science buildings in Europe and aimed at easing the shortage of specialist research space in London.

Barclays and Emirates NBD also pledged capital, bringing total financing to £368.5m. The project is due for completion in 2028.

Business, Innovation, Science and Trade Secretary Jonathan Reynolds said: "The UK is a genuine world-leader in life sciences, and One North Quay… will bolster that reputation."

The strategy, in short, runs on two tracks: capital for companies and laboratories for them to work in. The bank is betting that together they can keep British science British.

via cityam.com (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

460 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetSW-86 / L7 · November 18, 2026